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 The serum pepsinogen (PG) level was determined in 81 
patients undergoing gastric examination, and the results 
were clinically compared with the results of the conventional 
primary screening for gastric cancer based on the inquiry 
and radiography of the upper digestive tract. The values of 
PG I and PG II in patients whose stomach was found to be 
normal (normal group) were almost the same as the re-
ported values, but their PG I /PG II ratio was somewhat 
smaller than the reported value. 
  The PG levels in the gastric ulcer, erosive gastritis and 
gastric polyp groups did not significantly differ from those 
in the normal group, while the screening based on the PG 
level was suggested to be potentially useful for discovery of 
atrophic gastritis, post-gastrectomy abnormality and 
duodenal ulcer. 
  Gastric cancer was discovered in four of the 81 cases (early 
cancer in one case and advanced cancer in three cases), and 
all were poorly-differentiated adenocarcinoma. When com-
pared with the normal group, only the PG I / II ratio was 
smaller in this group. If this PG method is employed for the 
primary screening, the false-positive rate is 35.5% (false-
negative rate:75% ), an 46.9% of subjects undergoing this 
screening will require a second examination. The discrep-
ancy between the results of this study and those reported 
earlier was surmised to be partly attributable to the facts 
that histological type was poorly-differentiated adenocar-
cinoma in all the patients with gastric cancer in this study 
and the mean age of all subjects was more than 10 year 
higher than that in the earlier report. Compared with the 
conventional screening method, the percentage of subjects 
requiring a second examination was higher by more than 
20%. It was concluded that further studies are necessary, 
including review of the criteria for judgment of gastric 
cancer.
Introduction 
 Pepsinogen (PG) is an inactive precursor of pepsin, an 
offensive factor involved in the developmental mechanism 
of peptic ulcers, and immunochemically-different two 
groups, pepsinogen I (PG I ) and pepsinogen II (PG II ), 
have been identified.')
 Their localization and distribution in the stomach differ 
from those in the duodenum; PG I exists in the fundic 
gland region, while PG II exists in not only the fundic 
gland region but also cardiac, pyloric and duodenal gland 
regions. It has been reported that, in healthy persons, only 
PG I is excreted into the urine. 2) 
 The presence of PG in the blood was first recorded by 
Van Calcar in 1912. About 50 years later, Miki et al. and 
Samloff et al. developed radioimmunoassay (RIA) a4>, of 
PG I and PG II in 1981 and enzyme linked immunosorbent 
assay (ELISA) ) of these in 1987; by these methods, it has 
become possible to determine the concentration of PG in 
the blood. Since then, the pathophysiological and clinical 
significance of PG has been rapidly elucidated."') The 
serum PG level is ralated to pathology, such peptic ulcers 
(particularly, recurrent intractable peptic ulcer), 
Zollinger-Ellison syndrome, pernicious anemia, renal 
failure, gastrectomized stomach, atrophic gastritis and 
acute gastric (mucosal) lesion. It is also expected that the 
serum PG level can be used as an indicator of screening for 
gastric cancer, and it has been being studied to this 
end. 3,6,7) 
 In 1988, DAINABOT Co. developed an RIA kit, and it has 
widely been used because of its convenient and highly-
reproducible nature. 6> With the objective of investigating 
whether serum PG level is useful as an indicator of gastric 
cancer in its primary screening, we determined, using said 
RIA kit, the levels of PG I and PG II in patients who 
visited our hospital to undergo examination for gastric 
cancer. This study is reported below. 
I . Subjects and Methods 
 The subjects of this study were 81 patients who visited 
our hospital to undergo examination for gastric cancer 
during the one-month period from October into November, 
1991. Their age ranged from 32 to 89 years (mean:55.6 ± 
12.0 years), and they consisted of 43 males and 38 females. 
In all 81 cases, PG I and PG II were determined, and either
upper digestive tract radiography or gastroduodenal 
endoscopy, or both, were performed. Determination of the 
serum PG I and PG II levels was requested to BML 
(Biochemical Medical Laboratory) and performed by the 
RIA method. 
 Parameters analyzed in this study were the PG I level, 
PG II level, PG I /PG II ratio, age and their correlation 
with diseases of the upper digestive tract (chronic gastri-
tis, paptic ulcer, gastric polyp, postgastrectomy abnor-
mality and gastric cancer). 
 Normal ranges of PG I , PG II and PG I /PG II values 
were defined as mean ± 2 S.D. of respective values in the 
normal group (patients found to be free of gastric dis-
eases). The statistical analysis was performed by 
Student's t-test and Welch's method, and P <0.05 was 
defined as statistically significant.
Table 1 The subjects who visited Matsuura municipal hospi-
tal for the purpose to undergo examination for gastric cancer 
during a month.
                       Male Female Total 
Normal 19 12 31 
Gastric ulcer 4 3 7 
Duodenal ulcer 2 2 4 
Gastroduodenal ulcer 0 1 1 
Gastric cancer 2 2 4 
Gastric polyp 1 4 5 
Gastrectomy 2 1 3 
Atrophic gastritis 10 9 19 
Erosive gastritis 3 4 7 
 Total 43 38 81
II. Results 
1. Results of Examination of Upper Digestive Tract (by 
radiography or endoscopy or both) 
 There were no particular abnormalities detected in 31 
cases (defined as the normal group), while some kind of 
abnormality was discovered in the remaining 50 cases. The 
abnormalities consisted of gastric ulcer in 7 cases, duode-
nal ulcer in 4 cases, gastroduodenal ulcer in one case, 
gastric cancer in 4 cases, gastric polyps in 5 cases, erosive 
gastritis in 7 cases, atrophic gastritis in 19 cases and 
abnormality relating to earlier partial gastrectomy in 3 
cases (Table 1). 
2. Serum PG I Level (Fig.1) 
 The mean value of the serum PG I in the 81 cases was 
52.2±31.1 ng/ml. The mean value in the male subjects was 
44.8 ± 24.4 ng/ml, while it was 60.6 ± 35.5 ng/ml in the 
female subjects; the PG I level was significantly(P<0.05) 
higher in the female group. In the normal group (n=31), 
the mean value was 53.7 ± 25.8 ng/ml. The mean values in 
each disease group were as follows: gastric ulcer (n=7), 4 
4.5 ± 21.7 ng/ml; duodenal ulcer (n=4), including gastro-
duodenal ulcer), 103.6 ± 61.7 ng/ml; gastric cancer (n=4), 
72.5 ± 28.8 ng/ml; gastric polyp (n=5), 55.4 ± 7.6 ng/ml; 
erosive gastritis (n=7), 40.0±13.7 ng/ml; atrophic gastri-
tis (n=19), 41.8 ± 20.5 ng/ml; and gastrectomy (n=3), 
15.9±7.4 ng/ml. When compared with the normal group, 
the PG I level was significantly (P<O.O1) higher in the 
duodenal ulcer group, while it was significantly (P<0.01) 
lower in the gastrectomy group. No significant difference 
was noted with the groups of gastric cancer, gastric polyp, 
gastric ulcer or chronic gastritis. 
3. Serum PG II Level (Fig.2) 
 The mean PG II value was 19.3 ± 11.8 ng/ml in all cases, 
16.3 ± 10.1 ng/ml in the male group, and 22.7 ± 12.6 ng/ml
Fig.1 Correlations between serum PG I levels in normal 
group, gastric ulcer group, gastric polyp group, atrophic 
gastritis group, gastrectomy group, and erosive gastritis 
group. 
Compared with normal subjects, serum PG I levels was 
significantly higher in duodenal ulcer patients (included one 
gastroduodenal ulcer patient), lower in gastrctomy patients. 
No significant different was not shown other groups.
Fig.2 Correlations between serum PG II levels in normal 
group, gastric ulcer group, gastric polyp group, atrophic 
gastritis group, gastrectomy group, and erosive gastritis 
group. 
Compared with normal subjects, PG II levels was signifi-
cantly higher in duodenal ulcer patients and gastric cancer 
patients, while it was significantly lower in gastrectomy 
patients.
Fig.3 Correlations between serum PG I / II ratio levels in 
normal group, gastric ulcer group, gastric polyp group, 
atrophic gastritis group, gastrectomy group, and erosive 
gastritis group. 
Compared with normal subjects, PG I /PG II ratio level was 
significantly lower in gastric ulcer patients, gastric cancer 
patients and atrophic gastritis patients.
in the female group. The difference between the male and 
female group was not significant. 
  In the normal group, the mean value was 17.4 ±11.4 ng/ 
ml. The mean values in each disease group were as follows: 
gastric ulcer, 18.8 + 9.7 ng/ml; duodenal ulcer, 30.3 ± 15.6 
ng/ml; gastric cancer, 32.9±6.7 ng/ml; gastric polyp, 22.9 
± 7.9 ng/ml; erosive gastritis, 14.2 ± 7.2 ng/ml; atrophic 
gastritis, 19.4 + 10.8 ng/ml ; and gastrectomy, 5.2 + 3.2 ng/ 
ml. When compared with the normal group, the mean level 
was significantly higher in the duodenal ulcer group 
(P<0.05), and gastric cancer group (P<0.05), while it 
was significantly lower in the gastrectomy group 
(P<0.05). 
4. PG I /PG II Ratio (Fig.3) 
 The mean value of the PG I /PG II ratio in the 81 cases 
was 3.2+1.7. The mean value in the male subjects was 3.2 
+-1.7, while it was 3.2 ± 1.6 in the female subjects; the 
difference was not significant. In the normal group, the 
mean value was 3.9±1.8. The mean values in each disease 
group were as follows: gastric ulcer, 2.4 ± 1.3; duodenal 
ulcer, 3.4±1.0; gastric cancer, 2.1±0.6; gastric polyp, 2.8 
±1.3; erosive gastritis, 3.8±2.2; atrophic gastritis, 2.4± 
1.3; and gastrectomy, 3.3+0.5. When compared with the 
normal group, the mean level was significantly lower in 
the gastric ulcer group (P<0.05), gastric cancer group 
(P<0.05) and atrophic gastritis group (P<0.01). 
Discussion 
 In Japan, the malignant tumor with the highest inci-
dence and the highest mortality is still gastric cancer. 
With this background, efforts have been made to develop a 
screening method which is simple, convenient and highly
specific for gastric cancer. Since 1962, fluorography of 
upper digestive tract has been employed as the method of 
primary mass screening for gastric cancer, and this 
approach has been effective to a considerable degree. 
However, problems relating to examination time and 
exposure dose of x-ray remain unsolved. The problem 
concerning the dose of x-ray can be avoided by introducing 
endoscopic approach, but it is more painful for patients 
than fluorography. In 1982, Ichinose et al.') reported that 
the serum pepsinogen (PG) level is a useful criterion for 
screening for gastric cancer. This finding has urged us to 
compare its effectiveness with that of the conventional 
screening method for gastric cancer. 
 We measured the serum PG level in all outpatients who 
visited our hospital during a one-month period using the 
PG I /PG II RIA kit of DAINABOT Co. and studied its 
relationship with diseases of the upper digestive tract. The 
normal value of PG is not affected by sex, human race, 
season, etc., but affected by aging.""') In our present 
study, the values of PG I and PG II in normal subjects did 
not differ from the reported values, but the PG I /PG II 
ratio in these subjects tended to be smaller than the 
reported ratio. This result is surmised to be due to the fact 
that the mean age of these subjects was larger by more 
than 10 years than that of the subject group in the earlier 
report. 
 In general, the value of PG I does not change during 
human life from the second decade through the seventh 
decade, while the value of PG II gradually increases from 
the second decade through the sixth decade, and the PG I / 
PG II ratio gradually decreases from the second decade 
through the sixth decade.') Similar tendencies were ob-
served in our present study as well. That is, the value of 
PG I was not dependent on age (y=0.66x +20.8; r2=0.21; 
NS), while the value of PG II tended to increase gradually 
with aging (y=0.45x -5.1; r2= 0.21; P<0.01). The PG I /P 
G II ratio tended to decrease gradually in association with 
aging (y=-0.06x+6.8; r2=0.142; P<0.05). 
 It is believed that the state of chronic gastritis and 
atrophy of the fundic gland can be estimated based on the 
value of PG and PG I /PG II ratio. Namely, Samaioff et 
al.") reported that the size of atrophic area in atrophic 
gastritis is significantly correlated with the value of PG 
I and PG I /PG II ratio. This is thought to be due to a 
reflection of the impaired exocrine function due to a 
decrease in the number or loss of the chief cells and 
parietal cells occurring in association with the progression 
of atrophy of the gastric mucosa.') In our present study, 
the PG I level did not differ significantly between the 
atrophic gastritis group and the normal group, but the P 
G I /PG II ratio was, as it was expected, significantly 
(P<0.01) smaller in the atrophic gastritis group. This is 
thought to indicate a relative decrease in the ability to 
secrete PG I . 
 It is generally believed that, in patients with gastric
ulcer, the value of PG II has been increased, and the PG I / 
PG II ratio has been decreased.',') In the seven cases of 
gastric ulcer in our present study, the serum PG I and P 
G II values did not differ from those in the normal group, 
while the PG I /PG II ratio was significantly smaller in 
the gastric ulcer group (P<0.05). An imbalance between 
offensive and defensive factors is involved in the etiology 
of peptic ulcers, and hence analysis of only pepsin, an 
offensive factor, and PG, the precursor of pepsin, may be 
insufficient. 
 In patients with duodenal ulcer, the serum gastrin value 
has been usually increased, and secretion of gastric juice 
has also been increased in many cases. Gastrin is known to 
stimulate production of pepsin.") Probably for this rea-
son, the increase in the PG I level is larger in duodenal 
ulcer than in gastric ulcer.' ") In fact, both the PG I and 
PG II levels were significantly higher in the duodenal ulcer 
group (P<0.05 for both). The PG I value in patients with 
recurrent ulcers has been reported to be high.') The subjects 
of the present study also included an interesting duodenal 
ulcer case with a PG I value of 208.5 ng/ml, a PG II value 
of 42.8 ng/ml and a PG I /PG II ratio of 4.8; the PG I 
value had been markedly increased, and duodenal ulcer had 
recurred three times during the previous two-year period. 
This case supports the report of Miki et al. 1') that the level 
of PG I predicts to some extent the risk of recurrence of 
ulcer in patients with peptic ulcers, especially duodenal 
ulcer. 
 The numbers of the patients with gastric polyps, gastric 
cancer and stomach undergoing gastrectomy were all 
small, and thus it was difficult to make detailed compari-
sons with the normal group. It is generally belived that the 
PG I value is comparatively small in patients with gastric 
polyps. This is considered to be due to atrophy, which is 
present along with gastric polyps.') 
 Gastric cancer was discovered in four of the 81 cases; 
three were advanced cancer, one was early cancer, and 
histological type was poorly differentiated adenoca-
rcinoma in all four cases. It is of little value to say any 
relationship between gastric cancer and the PG level based 
on the data from these four cases. In this connection, it has 
been reported that the PG I value is generally small and 
PG I /PG II ratio is generally decreased in gastric cancer 
cases.",") This is surmised to be due to the fact that 
well-differentiated adenocarcinoma develops in atrophic 
mucosa. Because the gastric cancer type poorly-
differentiated adenocarcinoma in all four cases, it is 
thought that there was no difference in the PG I level and 
only PG I /PG II ratio was small. 
 The gastrectomy of the three cases was partial resection 
in all cases, and both the PG I and PG II values were 
significantly low compared with respective value in the 
normal group. As a matter of course, a decrease in the 
number of secretory cells is thought to be reflected on the 
level of PG of patients with resected stomach.
 The Study Group on the pepsinogen RIA kits established 
the following criteria for judgment of gastric cancer in 
screening for gastric cancer based on the data obtained in 
various districts of Japan'): PG I <70 and PG I /PG II < 
3.0. When these criteria were applied to the results of the 
present study, 38 (46.9%) of the 81 cases can be judged to 
be positive for gastric cancer. Of the 31 cases in the normal 
group, 11 cases test positive based on these criteria. 
Consequently, the false-positive rate is 35.5%. Of the four 
cases in the gastric cancer group, only one case tests 
positive by the criteria. As described earlier, all these four 
cases had poorly-differentiated adenocarcinoma, and it is 
thus thought that screening based on PG level is inappro-
priate for these cases. On the other hand, in the 19 cases of 
atrophic gastritis, which is believed to be likely to develop 
well-differentiated adenocarcinoma,11 cases (58.9%) test 
positive based on the criteria; PG level is therefore 
thought to be more effective for screening of well-
differentiated adenocarcinoma. 
 As described above, it is thought that the serum PG level 
as determined using the PG I /PG II RIA kit reflects well, 
as has been pointed out, the pathological and physiological 
state of secretion of acid and pepsin in gastric/duodenal 
diseases. In the present study, this approach using PG level 
was not very effective as a supportive means for diagnosis 
of gastric ulcer, erosive gastritis or gastric polyp, but it is 
thought to be useful for screening for atrophic gastritis, 
post-gastrectomy diseases and duodenal ulcer. However, 
our study demonstrated that 1) only 25.0% of the gastric 
cancer cases tested positive for this PG method, although 
the histological type was poorly-differentiated adeno-
carcinoma in all cases, and 2) when judged solely based on 
this method, as high as 46.9% of all the subjects, or nearly 
half, would require a second examination for gastric 
cancer. These results indicate that the screening using PG 
cannot replace, at least in this point of time, the conven-
tional inquiry method plus fluorography of the upper 
digestive tract. It is necessary to conduct further studies 
on this approach, including revision of the criteria for 
judgment. 
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